Skip to main content
Premium Trial:

Request an Annual Quote

Profitable Affy Tops In Revenue, Income

Premium

There’s Affymetrix, then the rest.

With the third-quarter financial reporting season completed, the numbers tell a story of a divergence in the public companies that BioArray News tracks in the microarray sector.

Affymetrix, which slipped into profitability, reporting a net income of $619,000 for the quarter, its first profitable quarter, is the only company among the five in the sector making more money that it spends.

— MOK

File Attachments
The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.